SEC Tracker
Get the app

ArriVent BioPharma AVBP

ArriVent BioPharma announces Phase 1b results

Item 7.01 Investor disclosure

Form
8-K
Filed
Importance
Routine
  1. Published Phase 1b results for firmonertinib
  2. Study FURMO-002 (NCT05364073) in Cancer Cell

Written from the 8-K on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when ArriVent BioPharma files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. Phibro Animal Health PAHC public float $764M, Dec 31, 2025
  2. uniQure QURE public float $765M, Jun 30, 2025
  3. Pacira BioSciences PCRX public float $758M, Jun 30, 2025
  4. Cogent Biosciences COGT public float $773M, Jun 30, 2025
  5. Immunome IMNM public float $729M, Jun 30, 2025